Malignant pleural mesothelioma (MPM) is a rare and aggressive cancer related to asbestos exposure. The first line regimen for MPM, consisting of a combination of cisplatin and the anti-metabolite pemetrexed, only increases patient survival by 3 months \[[@CR1]\]. The late diagnosis of the disease is partly responsible for the poor outcome in MPM. Thus, the identification of new biomarkers with diagnostic/prognostic and/or therapeutic properties would be useful to improve the therapeutic care of patients and the outcome of the disease. Soluble biomarkers have the advantage of being easily measured in fluid samples without the need to resort to invasive procedures and also to be targetable using antibodies. Previously identified MPM soluble biomarkers, soluble mesothelin-related peptide (SMRP) and fibulin-3, are too limited to be used routinely in clinic and are not identified as therapeutic target \[[@CR2]\]. Therefore, the identification of new soluble biomarkers with improved or complementary properties is required.

In a previous study, we identified BDNF, a neurotrophin, as an interesting biomarker for MPM \[[@CR3]\]. In this work, we aimed at examining this potential using collections of MPM samples. We also studied the implication of BDNF in MPM pathology.

Results and discussion {#Sec1}
======================

BDNF mRNA expression in MPM tumors and prognostic value {#Sec2}
-------------------------------------------------------

Previous transcriptomic data show an overexpression of *BDNF* gene expression in MPM cell lines compared to lung adenocarcinoma cell lines (Additional file [1](#MOESM1){ref-type="media"}: Figure S1) \[[@CR3]\]. To confirm these results, *BDNF* expression was measured in 179 MPM tumor samples and 26 normal pleura (Additional file [2](#MOESM2){ref-type="media"}: Table S1.1). Figure [1a](#Fig1){ref-type="fig"} confirms the significant higher expression of *BDNF* in MPM tumors compared to normal pleura (*p* = 0.0006). *BDNF* showed differential expression between MPM subtypes (*p* = 0.0011) with a lower expression in epithelioid MPM (EM) than in sarcomatoid (SM) and desmoplastic (DM) MPM (Additional file [3](#MOESM3){ref-type="media"}: Figure S2A).Fig. 1*BDNF* mRNA expression in MPM tumors and prognostic value. **a**, **b** Data from frozen MPM tumors samples collection **a** mRNA expression of *BDNF* in MPM tumors and normal pleura. Red bars correspond to median. \*\*\**p* \< 0.001. **b** Overall survival of MPM patients. Patients were separated in "high expression" and "low expression" groups based on the *BDNF* mRNA expression median and differences in survival between two groups are assessed by log-rank tests. **c**-**e**) Data from TCGA database. **c** mRNA expression of *BDNF* in MPM tumors, lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Red bars correspond to median. \*\*\**p* \< 0.001. **d** Overall survival of MPM patients. Patients were separated in "high expression" and "low expression" groups based on the *BDNF* mRNA expression median and differences in survival between two groups are assessed by log-rank tests. **e** Expression of *BDNF* mRNA in 37 different cancers. Arrow indicates mesothelioma *BDNF* expression. Black horizontal line corresponds to median of *BDNF* mRNA expression in MPM samples

*BDNF* expression and overall survival of patients were related (Fig. [1b](#Fig1){ref-type="fig"} and Additional file [4](#MOESM4){ref-type="media"}: Table S2). Indeed, patients with high *BDNF* had a lower survival than patients with low *BDNF* (15.9 versus 21.1 months, *p* = 0.0736) and this survival difference is significant at 3 years (*p* = 0.0401).

These observations were confirmed using TCGA database (Additional file [2](#MOESM2){ref-type="media"}: Table S1.2). Expression of *BDNF* was significantly higher in MPM than in lung squamous carcinoma and lung adenocarcinoma (Fig. [1c](#Fig1){ref-type="fig"}). As previously observed, high *BDNF* was associated with low survival compared to low *BDNF* (12.4 versus 27.5 months, *p* \< 0.0001) (Fig. [1d](#Fig1){ref-type="fig"} and Additional file [4](#MOESM4){ref-type="media"}: Table S2). *BDNF* was already described as overexpressed in several other cancers \[[@CR4]\]. In TCGA cohort, we observed that MPM has the highest *BDNF* expression among 37 tumor types indicating that *BDNF* gene overexpression is a hallmark of MPM (Fig. [1e](#Fig1){ref-type="fig"} and Additional file [5](#MOESM5){ref-type="media"}: Table S3). These results were confirmed at the mRNA level and using Immunofluorescence on cancer cell lines and commercial primary mesothelial cells (MC) (Additional file [6](#MOESM6){ref-type="media"}: Figure S3A-B).

Expression of BDNF in pleural effusions from patients {#Sec3}
-----------------------------------------------------

In our collection of pleural effusions (PE) (Additional file [2](#MOESM2){ref-type="media"}: Table S1.3), a significant higher BDNF level was observed in MPM samples (median, 95.26 pg/ml) compared to other neoplasia or benign samples (BPE) (median, 28.08 pg/ml and 8.87 pg/ml) (Fig. [2a](#Fig2){ref-type="fig"}) and also to all PE (malignant and non-malignant) (median, 23.33 pg/ml) (Fig. [2b](#Fig2){ref-type="fig"}) according to the mRNA results. No significant difference in BDNF level was observed between the MPM subgroups (Additional file [3](#MOESM3){ref-type="media"}: Figure S2B).Fig. 2Diagnostic and prognostic value of BDNF in pleural effusions from patients. Pleural fluid BDNF values **a** in patients with MPM, other neoplasia or BPE or **b** in patients with MPM or other effusions (neoplasia and BPE). Red bars correspond to median. \*\*\**p* \< 0.001. MPM. malignant pleural mesothelioma; BPE. benign pleural effusion. **c** ROC curve for BDNF to distinguish between patients with MPM and patients with other malignant and/or benign effusions. **d** Overall Survival of MPM patients. Patients were separated in "high expression" and "low expression" groups based on the BDNF expression median in MPM PE and differences in survival between two groups are assessed by log-rank tests

These results confirmed a preliminary observation by Duysinx and colleagues performed on only 10 MPM PE \[[@CR4]\] and can be explained, in part, by the ability of MPM cells to produce high level of BDNF (Additional file [6](#MOESM6){ref-type="media"}: Figure S3C). This growth factor can also be produced by a large variety of cells \[[@CR5]\] explaining its presence in other PE, but at a lower amount.

Area under the curve (AUC) of BDNF to differentiate MPM from other neoplasia or all PE were similar (AUC = 0.6710 ± 0.04 and AUC = 0.6972 ± 0.038) (Fig. [2c](#Fig2){ref-type="fig"} and Additional file [7](#MOESM7){ref-type="media"}: Table S4.1). The best specificity and sensitivity for BDNF were \~ 86.05% and \~ 49.51% (Additional file [7](#MOESM7){ref-type="media"}: Table S4.2).

The diagnostic value of BDNF (AUC = 0.69) seems slightly lower than the one of SMRP (AUC = 0.76 to 0.87) \[[@CR6]\], the best MPM soluble biomarker to date. However, BDNF is expressed by all subtypes of MPM unlike SMRP which is not expressed by SM \[[@CR2]\]. Then, an association of these two biomarkers has a strong potential to improve the sensitivity and the specificity of MPM diagnosis. Comparison of BDNF diagnostic value with fibulin-3 is currently complicated due to heterogeneity in the results obtained with this biomarker \[[@CR2]\].

Prognostic value of BDNF in pleural effusions from patients {#Sec4}
-----------------------------------------------------------

In several cancers, BDNF was described as overexpressed in the tumor environment \[[@CR4], [@CR7]\] and can be associated with poor survival \[[@CR8]\]. Then, we evaluated the prognosis value of BDNF in MPM PE. Interestingly, as in mRNA study, patients with BDNF above median presented a significantly lower survival than the others (8.3 versus 13 months; *p* = 0.0061) (Fig. [2d](#Fig2){ref-type="fig"} and Additional file [4](#MOESM4){ref-type="media"}: Table S2). This association between high BDNF and poor survival suggests an implication of this protein in the development of the pathology.

Whereas prognostic value of SMRP remains inconclusive \[[@CR2]\], patients with high BDNF have a shorter survival than patients with low BDNF. In PE, this observation is not related to MPM subtype. Indeed, in this cohort, SM, the most aggressive subtype of mesothelioma, only represent 7% of the cases and therefore cannot be responsible for this result. In PE, these characteristics are similar to the prognostic value of Fibulin-3 \[[@CR2]\].

Evaluation of BDNF on angiogenesis {#Sec5}
----------------------------------

Several studies have demonstrated a pro-tumoral autocrine action of BDNF on cancer cells \[[@CR8]\]. To evaluate this activity on MPM cells, expressions of BDNF receptors (TrkB and p75NTR) were measured first. Additional file [8](#MOESM8){ref-type="media"}: Figure S4A showed a heterogeneous and significant reduced expression of TrkB in MPM cells compared with MC. p75NTR expression was also heterogeneous in MPM cells and similar to MC (Additional file [8](#MOESM8){ref-type="media"}: Figure S4B). Figure [3a](#Fig3){ref-type="fig"} and [b](#Fig3){ref-type="fig"} show that BDNF had no effect on MPM cell growth and sensitivity to cisplatin. These results suggest that BDNF has no autocrine action on MPM cells.Fig. 3Evaluation of BDNF activity on MPM cells and on PE-induced HUVEC proliferation. **a** Effect of BDNF on MPM cell growth. **b** Effect of BDNF on cisplatin toxicity on MPM cells. **c** Effect of an anti-BDNF blocking antibody on MPM pleural effusion-induced HUVEC proliferation (*n* = 14). Red bars correspond to median. **d** Segregation of pleural effusions in sensitive (*n* = 11) and resistant (*n* = 3) groups according to the anti-BDNF blocking antibody activity

BDNF was also described as involved on angiogenesis in different cancer types \[[@CR9]\]. We thus studied this property by measuring the induction of HUVEC proliferation. First, we showed that MPM PE induced angiogenesis by leading to an increase of HUVEC tube formation and proliferation (Additional file [9](#MOESM9){ref-type="media"}: Figure S5A-B). Figure [3c](#Fig3){ref-type="fig"} shows that an anti-BDNF blocking antibody (from rabbit, Abcam) reduced significantly by \~ 31% the MPM PE-induced HUVEC proliferation. A detailed analysis of the results led to the segregation of the MPM PE in a sensitive group to BDNF blocking (*n* = 11) and in a resistant group (*n* = 3) (Fig. [3d](#Fig3){ref-type="fig"}). These results were confirmed using another anti-BDNF blocking antibody (from chicken, Abcam) (Additional file [9](#MOESM9){ref-type="media"}: Figure S5C).

These observations demonstrate the strong implication of BDNF in the PE-induced angiogenesis. However, the resistance of some PE to the blocking antibody demonstrates that BDNF is not the only player participating to this process. This is also supported by the observation that the activity of the blocking antibody is not correlated to BDNF concentrations in PE (Additional file [10](#MOESM10){ref-type="media"}: Figure S6). Previous works have shown that, in some cancers, BDNF can induce expression of the vascular endothelial growth factor (VEGF), well known to induce angiogenesis, \[[@CR9]\]. Thus, we measured VEGF in MPM PE. No evident correlation between BDNF and VEGF was observed (Additional file [11](#MOESM11){ref-type="media"}: Figure S7A). However, we did not observe samples with high BDNF and low VEGF. Moreover, in PE with BDNF higher than median value, a positive correlation with VEGF was observed (Additional file [11](#MOESM11){ref-type="media"}: Figure S7B). This suggests that VEGF can be dependent of BDNF in some PE. As observed for BDNF, the activity of the blocking antibody was not correlated to VEGF concentrations (Additional file [11](#MOESM11){ref-type="media"}: Figure S7C). These results show that VEGF cannot explain anti-angiogenic effect of the BDNF blocking antibody.

Recently, in the MAPS study, it was shown that the combination pemetrexed/cisplatin in association with bevacizumab (anti-VEGF) improves overall survival of MPM patients \[[@CR10]\]. This clinical trial demonstrates the interest of targeting angiogenesis in MPM. Regarding our results, this suggests that BDNF could be an interesting target in MPM due to its implication in this process.

Conclusion {#Sec6}
==========

Our work identifies BDNF as new interesting MPM biomarker. Moreover, due to its implication in angiogenesis, BDNF could also be a new potential therapeutic target.
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